Posted by Michael Wonder on 28 Jan 2025
Beckman Coulter receives FDA breakthrough device designation for Alzheimer's disease blood test
28 January 2025 - Beckman Coulter today announced the US FDA has granted breakthrough device designation to Beckman Coulter's Access p‑Tau217/β-Amyloid 1-42 plasma ratio.
This blood test is designed to aid health care providers identify patients with amyloid pathology associated with Alzheimer's disease.
